Online citations, reference lists, and bibliographies.
← Back to Search

Incorporation Into A Biodegradable Hyaluronic Acid Matrix Enhances In Vivo Efficacy Of Recombinant Human Interleukin 11 (rhIL11).

A. Takagi, N. Yamashita, T. Yoshioka, Yuuki Takaishi, K. Nakanishi, S. Takemura, A. Maeda, K. Saito, Y. Takakura, M. Hashida
Published 2006 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
In order to improve the therapeutic efficacy of recombinant human interleukin 11 (rhIL11) and to reduce its frequency of administration, the feasibility of a sustained release formulation consisting of hyaluronic acid (HyA) was investigated. rhIL11 was mixed together with an aqueous solution of HyA or HyA and protamine, and the mixture was lyophilized. The resulting powder was compressed into pellet and was subcutaneously administered in the rats. The plasma profile of rhIL11 was determined by ELISA. The mean residence time and t(max) of rhIL11 were much prolonged by administration in an HyA pellet. The additional incorporation of protamine into the formulation further enhanced the plasma duration of the protein. Separately, peripheral platelet counts were measured for several rhIL11-containing solution and pellets. Platelet counts much increased after administration of rhIL11-containing pellets, whereas the effect of bolus subcutaneous administration of rhIL11 solution was limited. The degree of platelet increase in rats treated with the pellets was comparable to that for rats treated with 1- or 2-day continuous infusion from an osmotic mini-pump; these data reflect the importance of increased plasma duration of rhIL11. These data indicate that use of hyaluronic acid as a polymer matrix might enhance the therapeutic efficacy of rhIL11.
This paper references
10.1016/S0168-3659(99)00146-7
DepoFoam technology: a vehicle for controlled delivery of protein and peptide drugs.
Qiaoming Ye (2000)
10.1073/PNAS.87.19.7512
Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine.
S. R. Paul (1990)
Constant subcutaneous infusion of rhIL-11 in mice: efficient delivery enhances biological activity.
J. Leonard (1996)
10.1016/J.BIOMATERIALS.2004.02.067
Crosslinked hyaluronic acid hydrogels: a strategy to functionalize and pattern.
Tatiana Segura (2005)
10.1182/BLOOD.V83.6.1499.1499
Recombinant human interleukin-11 stimulates multilineage hematopoietic recovery in mice after a myelosuppressive regimen of sublethal irradiation and carboplatin.
J. Leonard (1994)
Disposition characteristics of recombinant human interleukin-11 after a bolus intravenous administration in mice.
A. Takagi (1995)
10.1016/S0169-409X(02)00020-0
Introduction and overview of peptide and protein pegylation.
Veronese Fm (2002)
10.1007/s002800051048
Effect of interleukin 11 on normal and pathological thrombopoiesis
M. Teramura (1996)
10.1163/1568562041753115
Anti-inflammatory drug delivery from hyaluronic acid hydrogels
S. Hahn (2004)
10.1163/1568562041753025
Hyaluronic-acid-based semi-interpenetrating materials
Xuejun Xin (2004)
10.1002/j.1460-2075.1994.tb06261.x
Identification of a common hyaluronan binding motif in the hyaluronan binding proteins RHAMM, CD44 and link protein.
B. Yang (1994)
10.1182/BLOOD.V89.11.3897
Interleukin-11: review of molecular, cell biology, and clinical use.
X. Du (1997)
10.1007/bf03165282
Thrombopoietin: from theory to reality
K. Kaushansky (1999)
10.1007/s002800051047
Thrombopoietic activity of recombinant human interleukin 11 in cancer patients receiving chemotherapy
M. Gordon (1996)
10.1111/j.1365-2249.1996.tb08288.x
Expression of interferon‐gamma (IFN‐δ), IL‐10, IL‐12 and transforming growth factor‐beta (TGF‐β) mRNA in synovial fluid cells from patients in the early and late phases of rheumatoid arthritis (RA)
A. Bucht (1996)
10.1038/NBT0890-755
Controlled Release of Interleukin-2 from Biodegradable Microspheres
M. Hora (1990)
10.1093/JAOAC/83.5.1053
Quantitative in vitro bioassay for recombinant human interleukin-11.
H. Yokota (2000)
10.1023/A:1012142204132
The Stabilization and Encapsulation of Human Growth Hormone into Biodegradable Microspheres
O. Johnson (2004)
Identification of two hyaluronan-binding domains in the hyaluronan receptor RHAMM.
B. Yang (1993)
10.1182/BLOOD.V87.9.3615.BLOODJOURNAL8793615
A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy.
M. Gordon (1996)
10.1016/S0168-3659(98)00148-5
Stabilization of proteins against methylene chloride/water interface-induced denaturation and aggregation.
H. Sah (1999)
10.2745/DDS.8.237
Sustained release preparation of erythropoietin using sodium hyaluronate.
Y. Igari (1993)
10.1182/BLOOD.V87.9.3607.BLOODJOURNAL8793607
A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy.
I. Tepler (1996)
10.1073/PNAS.89.9.4013
Growth factor requirements for survival in G0 and entry into the cell cycle of primitive human hemopoietic progenitors.
A. G. Leary (1992)
10.2165/00002018-200023020-00003
A Risk-Benefit Assessment of Injections of Hyaluronan and its Derivatives in the Treatment of Osteoarthritis of the Knee
M. E. Adams (2000)
10.1182/BLOOD.V81.4.901.BLOODJOURNAL814901
Recombinant human interleukin-11 stimulates megakaryocytopoiesis and increases peripheral platelets in normal and splenectomized mice.
T. Neben (1993)
10.1111/j.1365-2141.1993.tb03020.x
Effect of recombinant human interleukin‐11 on rat megakaryopoiesis and thrombopoiesis in vivo: comparative study with interleukin‐6
Y. Yonemura (1993)
Cytoprotective effects of hyaluronic acid and Carbomer 934P in ocular surface epithelial cells.
C. Debbasch (2002)



This paper is referenced by
10.1002/APP.25993
Comparison of the Effectiveness of Four Different Crosslinking Agents with Hyaluronic Acid Hydrogel Films for Tissue-Culture Applications
M. Collins (2007)
Author names and affiliations
Y. Xie (2011)
10.1016/j.ejpb.2017.05.013
The pharmacokinetic and pharmacodynamic properties of site‐specific pegylated genetically modified recombinant human interleukin‐11 in normal and thrombocytopenic monkeys
S. Ma (2017)
10.1002/jps.24243
Formulation and stability of cytokine therapeutics.
T. Lipiäinen (2015)
10.1166/JBN.2014.1878
Self-assembled hyaluronate/protamine polyelectrolyte nanoplexes: synthesis, stability, biocompatibility and potential use as peptide carriers.
A. Umerska (2014)
10.1016/j.jconrel.2011.03.021
Hyaluronic acid: evaluation as a potential delivery vehicle for vitronectin:growth factor complexes in wound healing applications.
Y. Xie (2011)
UNIVERSIDADE FEDERAL DE SANTA MARIA CENTRO DE CIÊNCIAS DA SAÚDE PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS FARMACÊUTICAS DESENVOLVIMENTO E VALIDAÇÃO DE MÉTODO POR CROMATOGRAFIA LÍQUIDA EM FASE REVERSA PARA AVALIAÇÃO DE INTERLEUCINA-11 HUMANA RECOMBINANTE. CORRELAÇÃO COM O BIOENSAIO
Ricardo Bizogne Souto (2011)
10.1016/J.JCONREL.2007.03.009
Enhanced pharmacological activity of recombinant human interleukin-11 (rhIL11) by chemical modification with polyethylene glycol.
A. Takagi (2007)
10.1002/APP.27631
Investigation of the swelling behavior of crosslinked hyaluronic acid films and hydrogels produced using homogeneous reactions
M. Collins (2008)
10.1016/j.jmbbm.2013.09.025
Fine tuning and measurement of mechanical properties of crosslinked hyaluronic acid hydrogels as biomimetic scaffold coating in regenerative medicine.
Caterina Credi (2014)
Semantic Scholar Logo Some data provided by SemanticScholar